Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 547.56M | 504.42M | 400.07M | 353.79M | 206.32M | 179.37M |
Gross Profit | 158.76M | 146.69M | 112.22M | 90.26M | 51.11M | 44.68M |
EBITDA | 105.74M | 95.80M | 68.95M | 56.35M | 30.04M | 25.46M |
Net Income | 63.47M | 58.98M | 44.92M | 41.79M | 15.89M | 13.37M |
Balance Sheet | ||||||
Total Assets | 642.64M | 629.00M | 404.14M | 377.54M | 334.13M | 203.20M |
Cash, Cash Equivalents and Short-Term Investments | 14.03M | 13.45M | 5.26M | 4.45M | 11.12M | 24.23M |
Total Debt | 198.54M | 206.03M | 46.04M | 55.00M | 84.36M | 2.21M |
Total Liabilities | 281.97M | 286.24M | 118.05M | 140.00M | 139.69M | 26.31M |
Stockholders Equity | 360.67M | 342.76M | 286.09M | 237.54M | 194.45M | 176.89M |
Cash Flow | ||||||
Free Cash Flow | 59.01M | 56.94M | 30.84M | 3.96M | 8.90M | 20.67M |
Operating Cash Flow | 69.75M | 66.59M | 41.33M | 17.74M | 14.29M | 25.04M |
Investing Cash Flow | -211.25M | -210.16M | -10.49M | 1.29M | -101.46M | -4.26M |
Financing Cash Flow | 144.41M | 152.39M | -30.02M | -25.89M | 74.05M | -285.00K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | $1.69B | 14.93 | 11.69% | 1.51% | 4.02% | 11.32% | |
73 Outperform | $1.61B | 24.21 | 19.29% | ― | 40.98% | 34.80% | |
64 Neutral | $1.24B | 17.00 | 4.76% | ― | -0.61% | ― | |
58 Neutral | $2.32B | ― | -376.89% | ― | 26.27% | 15.58% | |
51 Neutral | $7.91B | -0.36 | -41.71% | 2.23% | 23.45% | -1.86% | |
50 Neutral | $1.22B | ― | -38.92% | ― | 3.53% | -2309.98% | |
49 Neutral | $863.54M | ― | -111.91% | ― | 25.84% | -47.67% |
UFP Technologies has released updated presentation materials for investor meetings, highlighting its strategic focus on the medical device industry. The company emphasizes its innovative process from design to delivery, aiming to strengthen customer relationships and expand in high-margin markets. The presentation outlines the company’s growth strategies, including shifting its business to higher-margin opportunities and expanding its presence in various markets such as medical, aerospace, and defense. These updates are expected to enhance UFP Technologies’ market positioning and operational efficiency, potentially impacting stakeholders positively.
On July 17, 2025, UFP Technologies announced the acquisition of UNIPEC and TPI, expanding its capabilities in the medical device market. UNIPEC, based in Rockville, Maryland, specializes in precision thermoformed and heat-sealed polymer components for implantable medical devices, enhancing UFP’s thin film platform. TPI, located in Anasco, Puerto Rico, manufactures precision thermoplastic injection-molded components, strengthening UFP’s thermoplastic molding capabilities. These acquisitions align with UFP’s strategy to grow in high-growth, high-barrier sectors, providing unique technologies and expertise that enhance partnerships with leading medical device OEMs.
UFP Technologies has released updated presentation materials for investor meetings, highlighting their strategic focus on expanding in the medical device market. The company emphasizes its expertise in design, materials, and global manufacturing, aiming to shift its business towards higher-margin opportunities and expand its presence in the medical, aerospace, defense, and other markets. This move is expected to strengthen UFP’s market positioning and enhance its growth potential, although investors are cautioned about the risks and uncertainties associated with forward-looking statements.
On June 4, 2025, UFP Technologies held its Annual Meeting of Stockholders where several key proposals were voted on. The stockholders elected seven directors to serve until the 2026 Annual Meeting, approved executive compensation, decided on the frequency of future votes on executive compensation, and ratified the appointment of Grant Thornton LLP as the independent registered public accounting firm for 2025.